Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Free Cash Flow (2016 - 2025)

OptimizeRx (OPRX) has disclosed Free Cash Flow for 16 consecutive years, with $7.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 2118.38% to $7.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.7 million through Dec 2025, up 290.56% year-over-year, with the annual reading at $18.7 million for FY2025, 290.56% up from the prior year.
  • Free Cash Flow hit $7.1 million in Q4 2025 for OptimizeRx, up from $3.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $7.1 million in Q4 2025 to a low of -$7.0 million in Q4 2023.
  • Historically, Free Cash Flow has averaged $1.3 million across 5 years, with a median of $1.5 million in 2021.
  • Biggest five-year swings in Free Cash Flow: crashed 949.35% in 2023 and later soared 2118.38% in 2025.
  • Year by year, Free Cash Flow stood at -$1.4 million in 2021, then surged by 297.08% to $2.7 million in 2022, then plummeted by 357.34% to -$7.0 million in 2023, then skyrocketed by 104.61% to $321000.0 in 2024, then skyrocketed by 2118.38% to $7.1 million in 2025.
  • Business Quant data shows Free Cash Flow for OPRX at $7.1 million in Q4 2025, $3.1 million in Q3 2025, and $4.6 million in Q2 2025.